Pancreatic ductal adenocarcinoma represents a disease with increasing incidence. Its prognosis is the worst among all malignancies despite the aggressive combined multimodal treatment across all stages. In metastatic disease, median survival is approximatelly one year. The mainstay of treatment is chemotherapy (neo/adjuvant, palliative) and in selected subgroups of patients even radiotherapy. Nevertheless, nowadays there are very few prognostic and/or predictive biomarkers available that can be used to identify and better stratify patients based on risk to tailored treatment. Potentially, promising areas of research are circulating tumor cells and circulating tumor DNA, which can be easily obtained from peripheral blood – so called liquid biopsy. They may serve as a tool to assess response to applied treatment, and to detect the emergence of treatment-resistant clones or early disease relapse. Moreover, their study may allow identification of potentially tumor-specific alterations, which may serve as target structures for targeted (tailored) therapy. Alternatively, different prognostic indexes/scores calculated by analysis of selected parameters of blood and/or biochemistry can be used to better stratify patients based on risk and better predict prognosis. The aim of this mini-review is to provide a basic overview of the current state of the art in this area and its potential significance for clinical practice.
Background/Aim: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. Patients and Methods: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. Results: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. Conclusion: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.
Biliary tract tumours represent a serious medical problem due to their high mortality rate. In early stages, patients are indicated for postoperative therapy after potentially curative surgery in order to reduce the risk of recurrence and prolong survival. Most patients with bile duct tumours are diagnosed at a locoregionally advanced and/or metastatic stage. The standard treatment for these patients is systemic therapy, now in combination with immunotherapy. Deepening knowledge of the molecular biology of this disease allows for the selection of treatment tailored to the individual patient based on the presence of specific targetable alterations in some patients. The article provides an overview of current treatment options for this disease across all stages.
Kazuistika popisuje případ pacientky s generalizovaným kolorektálním karcinomem do jater a plic. U pacientky byla po dvou letech od zahájení paliativní systémové onkologické terapie dosažena kompletní remise jaterních a plicních metastáz při druhé linii paliativní systémové léčby FOLFIRI + aflibercept. Klíčová slova: kolorektální karcinom, jaterní metastázy, plicní metastázy, paliativní chemoterapie, kompletní remise
Cholangiocelul?rn? karcinom, i kdy? se nejedn? o ?astou malignitu, p?edstavuje vzhledem k vysok? mortalit? s n?m spojen? z?va?n? medic?nsk? probl?m. Pacienti v ?asn?ch stadi?ch po potenci?ln? kurativn?m chirurgick?m v?konu jsou indikov?ni k po... Cholangiocelul?rn? karcinom, i kdy? se nejedn? o ?astou malignitu, p?edstavuje vzhledem k vysok? mortalit? s n?m spojen? z?va?n? medic?nsk? probl?m. Pacienti v ?asn?ch stadi?ch po potenci?ln? kurativn?m chirurgick?m v?konu jsou indikov?ni k po...